State Street Corp boosted its holdings in shares of Flexion Therapeutics, Inc. (NASDAQ:FLXN) by 66.3% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 1,379,202 shares of the specialty pharmaceutical company’s stock after purchasing an additional 549,948 shares during the period. State Street Corp owned approximately 4.32% of Flexion Therapeutics worth $27,888,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of FLXN. Fiduciary Trust Co. purchased a new position in Flexion Therapeutics during the 2nd quarter worth $101,000. IFP Advisors Inc grew its position in Flexion Therapeutics by 24.5% during the 2nd quarter. IFP Advisors Inc now owns 5,080 shares of the specialty pharmaceutical company’s stock worth $103,000 after purchasing an additional 1,000 shares during the last quarter. Advisor Group Inc. grew its position in Flexion Therapeutics by 205.9% during the 2nd quarter. Advisor Group Inc. now owns 5,200 shares of the specialty pharmaceutical company’s stock worth $105,000 after purchasing an additional 3,500 shares during the last quarter. Voya Investment Management LLC grew its position in Flexion Therapeutics by 25.8% during the 2nd quarter. Voya Investment Management LLC now owns 12,914 shares of the specialty pharmaceutical company’s stock worth $261,000 after purchasing an additional 2,651 shares during the last quarter. Finally, BB&T Securities LLC purchased a new stake in shares of Flexion Therapeutics in the second quarter valued at about $289,000. 72.04% of the stock is currently owned by institutional investors.

In related news, insider Yamo Deniz bought 3,000 shares of the stock in a transaction that occurred on Friday, September 1st. The stock was purchased at an average cost of $24.15 per share, for a total transaction of $72,450.00. Following the completion of the acquisition, the insider now owns 5,000 shares in the company, valued at $120,750. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Michael D. Clayman bought 5,000 shares of the stock in a transaction that occurred on Wednesday, November 8th. The stock was bought at an average price of $23.60 per share, with a total value of $118,000.00. Following the completion of the acquisition, the insider now owns 35,395 shares of the company’s stock, valued at approximately $835,322. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 10,375 shares of company stock valued at $249,575. 15.98% of the stock is currently owned by company insiders.

Several analysts have recently weighed in on the stock. Zacks Investment Research raised shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, August 28th. ValuEngine raised shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $44.00 target price on shares of Flexion Therapeutics in a report on Thursday, August 10th. Needham & Company LLC reaffirmed a “buy” rating and issued a $36.00 target price on shares of Flexion Therapeutics in a report on Sunday, September 17th. Finally, Northland Securities reaffirmed a “buy” rating and issued a $40.00 target price on shares of Flexion Therapeutics in a report on Friday. One analyst has rated the stock with a sell rating, two have given a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $98.33.

Flexion Therapeutics, Inc. (NASDAQ FLXN) opened at $23.99 on Friday. The company has a debt-to-equity ratio of 0.87, a current ratio of 12.93 and a quick ratio of 18.29. Flexion Therapeutics, Inc. has a 52-week low of $15.96 and a 52-week high of $32.25.

TRADEMARK VIOLATION NOTICE: This article was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.watchlistnews.com/flexion-therapeutics-inc-flxn-position-lifted-by-state-street-corp/1697566.html.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Institutional Ownership by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.